Back to News
Market Impact: 0.35
Novo CEO says pills could capture 50% of weight-loss market by 2030
Source: reuters.com
Healthcare & BiotechCorporate Guidance & OutlookProduct Launches
Novo Nordisk's CEO said oral weight-loss pills could account for as much as 50% of the global obesity-drug market by 2030. The company is positioning for a market shift from weekly injectable treatments to pills, highlighting a significant long-term growth opportunity in obesity care.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
NVO0.45
More News
- Hims & Hers stock climbs on direct partnership with Eli Lilly for obesity drugs
- Why is Hims & Hers Health stock rallying today?
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- A ‘geologic freak’ called the Smackover may end America’s lithium dependence on China, and Big Oil is already there
- Investing in Prediction Markets Will Pay Off, DraftKings CEO Says